Boardroom Alpha
Start trial
8-K primary document
INMB · Current Report (Form 8-K) · Filed July 1, 2026

Inmune Bio Inc — 8-K exhibit

ea029662401ex4-1.htm
Inmune Bio Inc on Boardroom Alpha

Exhibit 4.1

 

FORM OF AMENDMENT TO WARRANT

 

This Second Amendment to Common Stock Purchase Warrant (this “Amendment”) is entered into and shall become effective as of the date on which INmune Bio Inc. a Nevada corporation (the “Company”) receives both (i) payment of the Amendment Consideration (as defined below) and (ii) a duly executed copy of this Amendment from the undersigned holder (“Holder”) (such date, the “Effective Date”).

 

WHEREAS, the Holder is the holder of that certain warrant issued by the Company to the Holder on April 24 or April 29, 2024 (the “Warrant”);

 

WHEREAS, the Company and the Holder desire to amend the Warrant as more particularly set forth below in exchange for the Amendment Consideration; WHEREFORE, the parties do hereby agree as follows:

 

1. The portion of the Warrant’s first paragraph:

 

“and on or prior to 5:00pm (New York City time) on June 30, 2026,”

 

is hereby amended and replaced with the following:

 

“and on or prior to 5:00pm (New York City time) on December 31, 2027”

 

2. As consideration for this Amendment, the Company has granted the Holder the option to exercise 50% of the warrant for a reduced exercise price of $1.40 per share of Common Stock and the Holder elected to exercise 50% of the warrant for such reduced price and has paid the Company such reduced exercised price (the “Amendment Consideration”). The effectiveness of this Amendment is expressly conditioned upon the Company’s receipt of the full Amendment Consideration.

 

3. The Holder must execute and return this Amendment to the Company, together with the Amendment Consideration, no later than June 30, 2026 (the “Execution Deadline”). If the Holder does not execute and return this Amendment, together with the Amendment Consideration, to the Company by the Execution Deadline, this Amendment shall be null and void and of no force or effect.

 

4. Except as expressly amended herein, all terms and conditions of the Warrant shall remain in full force and effect.

 

5. This Amendment shall be governed by and construed in accordance with the laws governing the Warrant.

 

6. This Amendment may be executed in counterparts, each of which shall be deemed an original, and shall be binding upon all parties, their successors and assigns, and all of which taken together shall constitute one and the same Amendment. A signature delivered by facsimile or email shall constitute an original.

 

[Signature Page Follows]

 

 

 

INmune Bio Inc.  
   
By:    
Name:    
Title:    
     
Holder:    
   
By:           
Name:    
Title:    

 

 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer